High-Grade Gliomas Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting high-grade gliomas clinical trials across 7 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Beijing, Beijing Municipality, China, Boadilla del Monte, Madrid, Spain, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


High-Grade Gliomas Trials at a Glance

9 actively recruiting trials for high-grade gliomas are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Beijing, Boadilla del Monte, and Columbus. Lead sponsors running high-grade gliomas studies include Children's National Research Institute, Dushu Lake Hospital Affiliated to Soochow University, and Beijing Biotech.

Browse high-grade gliomas trials by phase

Treatments under study

About High-Grade Gliomas Clinical Trials

Looking for clinical trials for High-Grade Gliomas? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High-Grade Gliomas trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High-Grade Gliomas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Early Phase 1

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Brain CancerGliomaHigh Grade Glioma+4 more
Eben Rosenthal38 enrolled1 locationNCT07210632
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentHigh-Grade Gliomas+4 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting
Phase 1Phase 2

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

GBMHigh-Grade GliomasBrain Gliomas
Dushu Lake Hospital Affiliated to Soochow University25 enrolled1 locationNCT06018363
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

GlioblastomaGrade III GliomaHigh-Grade Gliomas+1 more
Medical University of Warsaw35 enrolled2 locationsNCT06975332
Recruiting
Phase 1

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas

High-Grade Gliomas
GONGCHU Biotechnology Co., Ltd35 enrolled1 locationNCT06660056
Recruiting
Not Applicable

Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery

High-Grade Gliomas
Kuopio University Hospital50 enrolled3 locationsNCT06740097